21384-44-1

Usage

Uses

Used in Organic Synthesis:
MAPM is utilized as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its unique structure and reactivity allow for the formation of new chemical bonds and the synthesis of pharmaceutically relevant compounds.
Used in Medicinal Chemistry:
In medicinal chemistry, MAPM is employed as a cytotoxic agent for cancer therapy. It is valued for its potential to induce DNA damage and disrupt cell cycle progression, which can lead to the inhibition of cancer cell growth.
Used in Cancer Research:
MAPM is also used in cancer research to study the mechanisms of cell death and to develop new therapeutic strategies against cancer. Its reactivity and ability to target cancer cells make it a promising candidate for further investigation and potential drug development.
Used in Drug Development:
Due to its potential as a cytotoxic agent, MAPM is explored in drug development for the creation of novel anticancer drugs. Its unique properties may contribute to the discovery of new pharmaceuticals that can effectively target and eliminate cancer cells while minimizing damage to healthy cells.

Upstream product

• 874-60-2 4-methyl-benzoyl chloride 
• 75-55-8 2-Methylaziridine 

Downstream Products

• 446313-54-8 tert-butyl {4-[2-(4-methylphenyl)-2-oxoethyl]-2-pyridyl}carbamate 
• 224038-61-3 [4-(4-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine 
• 446313-57-1 4-[2-ethyl-4-(4-methylphenyl)-1,3-thiazol-5-yl]pyridin-2-amine 
• 100866-13-5 1-(4-methylphenyl)-2-(4-pyridyl)ethanone 

Relevant academic research and scientific papers

Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as selective adenosine A3 antagonists

To investigate the potency of an adenosine A3 receptor (A 3AR) antagonist as an anti-asthmatic drug, a novel series of 4-phenyl-5-pyridyl-1,3-thiazole derivatives was synthesized and evaluated in human adenosine A1, A

Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as p38 MAP kinase inhibitors

A novel series of 4-phenyl-5-pyridyl-1,3-thiazole analogues possessing potent in vitro inhibitory activity against p38 mitogen-activated protein kinase and the release of tumor necrosis factor-α (TNF-α) from human monocytic THP-1 cells stimulated by lipopolysaccharide has been identified. Subsequent structure-activity relationship (SAR) studies and optimization for absorption, distribution, metabolism, and elimination (ADME) profiles led to the identification of compounds 7g and 10b as orally active lead candidates that block the in vivo production of proinflammatory cytokine (TNF-α). In pharmacokinetic studies, compound 10b showed good oral administration in mice and demonstrated significant in vivo anti-inflammatory activity in an anti-collagen monoclonal antibody-induced arthritis mouse model (minimum effective dose (MED)=30 mg/kg). Further elucidation of this class of compounds may provide novel anti-inflammatory agents, such as anti-rheumatoid arthritis drugs.

JNK INHIBITOR

The present invention relates to a c-Jun N-terminal kinase inhibitor containing an azole compound (I) substituted by a nitrogen-containing aromatic group having substituent(s)(except a compound represented by the formula: ) or a salt thereof or a prodrug thereof.

Adenosine A3 receptor antagonists

A pharmaceutical composition for antagonizing adenosine at adenosine A3receptors which comprises a 1,3-azole compound substituted on the 4- or 5-position, or both, by a pyridyl which may be substituted is provided and can be used as a prophylactic and therapeutic agent for asthma, allergosis, inflammation, and so on.